2021 Archives - The Office of Health Economics (OHE)

Search the Knowledge Hub

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Henderson N., Errea M., Skedgel C. and Jofre-Bonet, M.

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Sampson, C. and Garau, M.

Multi-Criteria Decision Analysis to Value Orphan Medicines

Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A.

Establishing a Reasonable Price for an Orphan Drug

Berdud, M., Drummond, M.F., and Towse, A.

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Towse, A. and Garau, M.

Orphan Drugs Policies: A Suitable Case for Treatment

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Martina Garau and Anna Bucsics

Recent Statistics on Orphan Approvals in Scotland and England

Martina Garau

Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

Mestre-Ferrandiz, J., Garau, M., O'Neill, P. and Sussex, J.

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M.

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Henderson, N., Firth, I., Errea, M., Skedgel, C. and Jofre-Bonet, M.

An analysis of orphan medicine expenditure in Europe: is it sustainable?

Jorge Mestre-Ferrandiz, Christina Palaska, Tom Kelly, Adam Hutchings, Adam Parnaby

Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches

Elena Nicod, Amanda Whittal, Michael Drummond, Karen Facey

The future of comparative effectiveness and relative efficacy of drugs: an international perspective

Donna A Messner, Adrian Towse, Penny Mohr, Martina Garau

Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What is Different About a One-Off Treatment?

Adrian Towse and Elisabeth Fenwick

Why are Patients in Need Not Getting Early Access to Life-Changing Medicines?

Hannah Schirrmacher, Isobel Firth and Grace Hampson

Making Outcome-Based Payment a Reality in the NHS

Cole, A., Cubi-Molla, P., Pollard, J., Sim, D., Sullivan, R., Sussex, J. and Lorgelly, P.

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

Firth, I., Schirrmacher, H., Hampson, G. and Towse, A.

Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK

Bernarda Zamora

How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?

Cole, A., Chan, A., Mujoomdar, M., Pichler, F. and Towse, A.

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

Marsden, G. and Towse, A.

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

Cole, A., Towse, A., Lorgelly, P., and Sullivan, R.

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M.

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

Marina Rodes Sanchez, Nadine Henderson and Lotte Steuten

Is the public supportive and willing to pay for a national assistive reproductive therapies programme? Results from a multicountry survey

Skedgel, C., Ralphs, E., Finn, E., Whitty, J., Markert, M., Samuelsen, C.

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Mott, D.J., Shah, K.K., Ramos-Goñi, J.M., Devlin, N.J. and Rivero-Arias, O.

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Brassel, S., Neri, M. and Steuten, L.

A Longer Life or a Quality Death? A Discrete Choice Experiment to Estimate the Relative Importance of Different Aspects of END-of-Life Care

Skedgel, C., Robinson, A.

Methods for Analysing and Reporting EQ-5D Data

Devlin, Nancy, Parkin, David, Janssen, Bas

#Book,
#Patient Outcomes,

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

Herdman, M., Kerr, C., Pavesi, M., Garside, J., Lloyd, A., Cubi-Molla, P. & Devlin, N.

Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?

Sampson, C., Parkin, D. and Devlin, N.

How do we Measure the “Value” in Value-Based care?

McKenna, I.

The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision

Article by: Lotte Steuten, Eleanor Bell & Margherita Neri

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Simon Brassel, Margherita Neri & Lotte Steuten

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Brassel, S. and Steuten, L.

Realising the Broader Value of Vaccines in the UK

Brassel, S., Neri, M., O’Neill, P. and Steuten, L.

Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit Patient Preferences

Mott, D.J., Chami, N. & Tervonen, T.

An exploration of methods for obtaining 0= dead anchors for latent scale EQ-5D-Y values

Shah, K.K., Ramos-Goñi, J.M., Kreimeier, S. and Devlin, N.J.

Additional Elements of Value for Health Technology Assessment Decisions

Karlsberg Schaffer, S., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J., Masterson, R., and Fischer, A

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Bernarda Zamora and Adrian Towse

International Valuation Protocol for the EQ-5D-Y-3L

Ramos-Goñi, J.M., Oppe, M., Stolk, E., Shah, K., Kreimeier, S., Rivero-Arias, O. & Devlin, N

A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. Applied Health Economics and Health Policy

David J. Mott, Grace Hampson, Martin J. Llewelyn, Jorge Mestre-Ferrandiz & Michael M. Hopkins

NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study

Nancy Devlin, Koonal Shah, Yan Feng

#Blog,
#Patient Outcomes,

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

Baltussen, R., Marsh, K., Thokala, P., Diaby, V., Castro, H., Cleemput, I., Garau, M., Iskrov, G., Olyaeemanesh, A., Mirelman, A., Mobinizadeh, M., Morton, A., Tringali, M., van Til, J., Valentim, J., Wagner, M., Youngkong, S., Zah, V., Toll, A., Jansen, M., Biklmakers, L., Oortwijn, W. and Broekhuizen, H.

OHE is Leading Research to Develop EQ-5D ‘Bolt-ons’ for Cognition and Vision

Chris Sampson

#Blog,
#Patient Outcomes,

Adult Versus Adolescent Preferences for EQ-5D-Y Health States

Koonal Shah

#Blog,
#Patient Outcomes,

Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA

Devlin, N., Lorgelly, P. and Herdman, M.

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Sampson, C. and Garau, M.

Distribution of the EQ-5D-5L Profiles and Values in Three Patient Groups

Feng, Y., Devlin, N., Bateman, A., Zamora, B., and Parkin, D.

End of Life Treatments, Societal Values, and ‘Overall’ Preference

Koonal Shah

#Blog,
#Patient Outcomes,

Generating Preference-based Values for the EQ-5D-Y to Support Its Use in HTA

Koonal Shah

#Blog,
#Patient Outcomes,

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Hampson, G., Mott, D., Devlin, N. and Shah, K

A note on the relationship between age and health-related quality of life assessment

Cubi-Molla, P., Shah, K.K., Garside, J., Herdman, M. and Devlin, N

Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective

Kreimeier, S., Oppe, M., Ramos-Goñi, J.M., Cole, A., Devlin, N., Herdman, M., Mulhern, B., Shah, K.K., Stolk, E., Rivero-Arias, O. & Greiner, W.

Two New Papers on EQ-5D-5L Valuation in Ireland

Koonal Shah

#Blog,
#Patient Outcomes,

A new method for valuing health: directly eliciting personal utility functions

Devlin, N., Shah, K., Mulhern, B., Pantiri, K. and van Hout, B.

Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders

Skedgel, C., Wranik, W., Hu, M.

Conducting a Time Trade-off Study Alongside a Clinical Trial: A Case Study and Recommendations

Shen, J., Hill, S., Mott, D., Breckons, M., Vale, L. & Pickard, R

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N.

A New Online Tool for Creating Personal and Social EQ-5D-5L Value Sets

Nancy Devlin

#Blog,
#Patient Outcomes,

Challenges in Valuing Temporary Health States for Economic Evaluation: A Review of Empirical Applications of the Chained Time Trade-Off Method

Stoniute, J., Mott, D.J. & Shen, J

Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Mott, D.

New Methods for Analysing the Distribution of EQ-5D Observations

Zamora, B., Parkin, D., Feng, Y., Bateman, A., Herdman, M., and Devlin, N.

Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets

Mulhern, B., Feng, Y., Shah, K., van Hout, B., Janssen, B., Herdman, M. and Devlin, N.

Comparing Preference-based Outcome Measures for Overactive Bladder: EQ-5D-5L vs OAB-5D

Herdman, M., Nazir, J., Hakimi, J., Siddiqui, E., Huang, M., Pavesi, M., MacDiamid, S., Drake, M.J., and Devlin, N

#Blog,
#Patient Outcomes,

The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review

Skedgel, C., Wranik, D., Hu, M.

A New Way of Presenting Health States in Valuation Studies

Cole, A., Shah, K., Mulhern, B., Feng, Y. and Devlin, N

#Blog,
#Patient Outcomes,

Effect of Religion on the Perception of Health States: A Qualitative Study

Elbarazi, I., Devlin, N.J., Katsaiti, M.S., Papadimitropoulos, E.A., Shah, K.K. and Blair, I.

#Blog,
#Patient Outcomes,

Valuing health-related quality of life: An EQ-5D-5L value set for England

Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B.

New methods for modelling EQ-5D-5L value sets: An application to English data

Feng, Y., Devlin, N., Shah, K., Mulhern, B. and Van Hout, B.

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health and quality of life outcomes.

Devlin, N., Herdman, M., Pavesi, M., Phung, D., Naidoo, S., Beer, T.M., Tombal, B., Loriot, Y., Ivanescu, C., Parli, T., Balk, M. & Holmstrom, S

Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies

Hampson, G., Towse, A. and Henshall, C.

An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D

Feng, Y., Herdman, M., van Nooten, F., Cleeland, C., Parkin, D., Ikeda, S., Igarashi, A. & Devlin, N.J

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

Marsden, G., Towse, A., Pearson, S.D., Dreitlein, B. and Henshall, C.

What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?

Devlin, N., Shah, K.K., and Buckingham, K.

Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L

Lorgelly, P.K., Doble, B., Rowen, D. Brazier, J

#Blog,
#Patient Outcomes,

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Garau, M., Marsden, G., Devlin, N., Amedeo Mazzanti, N. and Profico, A.

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Shah, K., Mulhern, B., Longworth, L. and Janssen, B.

The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison

Skedgel, C.

The Application of Anchoring Vignettes to the EQ-5D-5L: A Possible Solution to Reporting Heterogeneity in PROMs

Paula Lorgelly

#Blog,
#Patient Outcomes,

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

What Determines the Shape of an EQ-5D Index Distribution?

Parkin, D., Devlin, N. and Feng, Y.

Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review

Herdman, M., Cole, A., Hoyle, C.K., Coles, V., Carroll, S. & Devlin, N

5 Things You Should Do with EQ-5D Data

Nancy Devlin

#Blog,
#Patient Outcomes,

Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy

Mott, D. & Najafzadeh, M.

An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates

Papadimitropoulos, M., Elbarazi, I., Blair, I., Katsaiti, M.S., Shah, K. and Devlin, N.

An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?

A Framework for Payer Assessment of the Value of New Technologies: A US Approach

Pearson, S.

Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment

Skedgel, C., Wailoo, A., Akehurst, R.

Constant-sum paired comparisons for eliciting stated preferences: a tutorial

Skedgel, C. & Regier, D.

Real Option Value and Path Dependence in Oncology Innovation

Cook, J.P.

Adjusting Patient Case Mix to Compare PROMs across Providers

Nuttall, D., Parkin, D. and Devlin, N

#Blog,
#Patient Outcomes,

Using MCDA to Assess the Value of Treatments for Rare Diseases

Approaches to Identifying, Measuring, and Aggregating Elements of Value

Towse, A. and Barnsley, P.

Assessing the Performance of the EQ-VAS in the NHS PROMs Programme

Feng, Y., Parkin, D. and Devlin, N.

Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences

Skedgel, C., Wailoo, A., Akehurst, R.